PGF and non-small cell lung carcinoma: Subsequent phase 2 studies with motesanib showed a consistent association between increased levels from baseline in PLGF and outcomes across different tumor types, including thyroid cancer, breast cancer, and non–small-cell lung cancer (NSCLC) [8], [18]–[20].